Bullfrog AI Holdings, Inc. Stock Price, News & Analysis

BullFrog AI (NASDAQ: BFRG) will present a technical talk titled "Human-in-the-Loop Agent Workflows with bfPREP™" at the AI Drug Discovery & Development Summit 2025 in Boston, November 18–20, 2025.

The presentation is part of Technical Insights Session 1 on Wednesday, November 19, 2025 and will describe how bfPREP™ operationalizes AI agents for reliable, reproducible data preparation in drug development, including structured outputs, stable schemas, and human validation. bfPREP™ is BullFrog AI’s data cleansing and preparation module within BullFrog Data Networks™, focused on clinical, omics, and real-world data.

The summit expects 500+ attendees and 100+ speakers and targets AI applications across discovery through clinical development.

BullFrog AI (NASDAQ: BFRG) announced an abstract accepted for presentation at the 2026 ASCO Gastrointestinal Cancers Symposium, Jan 8–10, 2026 in San Francisco.

The poster, titled “Data-driven subtyping and differential glufosfamide benefit in pancreatic adenocarcinoma,” will be presented in Poster Session B on January 9, 2026 and published in the ASCO GI online proceedings and the Journal of Clinical Oncology supplement. The study, co-authored with Eleison Pharmaceuticals and investigators at Moffitt Cancer Center, uses BullFrog AI’s bfLEAP and bfPREP platforms to identify patient subtypes with potential enhanced response to glufosfamide.

BullFrog AI (NASDAQ: BFRG) will host an exclusive live investor webinar and Q&A on October 30, 2025 at 4:15 p.m. ET, presented by RedChip Companies and led by founder and CEO Vin Singh. The presentation will cover BullFrog AI’s AI-driven drug discovery platforms, including the BullFrog Data Networks™ Solutions Library powered by the proprietary bfLEAP™ causal AI engine and the newly launched bfPREP™ module for automated data cleansing and standardization.

The company will discuss its scalable, plug-and-play toolkit for the drug development lifecycle and strategic global collaborations, including a partnership with CRO Sygnature Discovery, which the release says is expected to expand commercial reach and drive significant revenue growth. A live Q&A will follow; registration is free at the listed RedChip webinar link.

BullFrog AI (NASDAQ: BFRG) announced the expansion of its internal sales organization to accelerate the commercialization of its clinical trial optimization solutions, including the recently launched bfPREP™ module. This expansion complements their existing partnership with Sygnature Discovery for BullFrog Data Networks™.

The dual-pronged commercial strategy includes: 1) Sygnature partnership focusing on selling target selection solutions to global biopharma clients, and 2) Direct sales team marketing bfPREP and clinical trial optimization tools. The bfPREP module, initially developed for Eleison Pharmaceuticals collaboration, standardizes diverse clinical trial data into analyzable formats within days.

BullFrog AI (NASDAQ: BFRG) has officially launched commercial sales of its BullFrog Data Networks™ platform through its partnership with Sygnature Discovery. The launch, which began on September 12, represents a potential $15-30 million revenue opportunity through 2028.

The AI-driven platform, designed for drug development and discovery, will be marketed to Sygnature's global biopharma client base. The platform's capabilities include target identification, mechanism-of-action analysis, patient stratification, drug repurposing, and clinical trial optimization. Sygnature's business development team has completed training to integrate BullFrog Data Networks™ into their drug discovery solutions portfolio.

BullFrog AI (NASDAQ: BFRG), a technology-enabled drug development company, will host a webinar on October 6, 2025 titled "Clinical Data Analysis with Agents: Reliable Automation with Human Oversight." The company's Director of AI, Dr. Juan Felipe Beltrán, will showcase how BullFrog's proprietary platforms bfPREP™ and bfLEAP™ transformed over 10,000 pages of unstructured clinical PDFs into OMOP-structured datasets.

The presentation will demonstrate how BullFrog AI combines automated processing with human oversight to ensure data integrity in clinical research workflows. The webinar will focus on practical applications of their technology for parsing clinical documents, standardizing medical vocabularies, and implementing template-driven agents for data transformation.

BullFrog AI (NASDAQ: BFRG) reported significant progress in its collaboration with Eleison Pharmaceuticals, showcasing the capabilities of its AI platforms bfPREP™ and bfLEAP®. The company successfully developed a new data ingestion module that converted over 10,000 pages of clinical trial PDFs into standardized datasets.

The collaboration demonstrated BullFrog AI's ability to handle complex clinical documentation through its enterprise-grade platforms. The bfPREP™ module, which emerged as a standalone commercial offering, transforms legacy clinical trial data into structured, actionable insights. The bfLEAP® analytics engine identified data-driven patient subgroups to enhance trial design and market positioning.

Following this success, both companies are preparing a joint scientific submission for an upcoming oncology conference and are discussing a potential second collaboration contract.

BullFrog AI Holdings (NASDAQ: BFRG), a technology-enabled drug development company leveraging AI and machine learning for pharmaceutical development, has announced its participation in BTIG's Annual Virtual Biotechnology Conference.

CEO Vin Singh will engage in a fireside chat on Wednesday, July 30, 2025, at 11:20 a.m. ET. The company will also be available for one-on-one meetings during the two-day conference, scheduled for July 29-30, 2025.

BullFrog AI (NASDAQ: BFRG) has released a white paper outlining a new approach to drug development using their proprietary bfLEAP™ platform. The platform, built on technology from Johns Hopkins University Applied Physics Lab, addresses the critical issue of high failure rates in drug development, where 90% of candidates fail in clinical trials.

The company's AI solution operates in a $200B+ market and is specifically designed for biological applications, offering composition-aware analytics across the entire drug development lifecycle. The platform's capabilities span early discovery, preclinical trials, and late-stage development, powered by causal AI and combinatorial modeling. With the AI drug discovery market projected to reach $35 billion by 2034, BullFrog AI's technology aims to reduce failure rates and accelerate development cycles through transparent, biology-native analytics.